Journal Article

DKFZ-2019-00882

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Relaxation-compensated APT and rNOE CEST-MRI of human brain tumors at 3 T.

Goerke, S. (First author)DKFZ* ; Soehngen, Y.DKFZ* ; Deshmane, A. ; Zaiss, M. ; Breitling, J.DKFZ* ; Boyd, P. S.DKFZ* ; Herz, K. ; Zimmermann, F.DKFZ* ; Klika, K.DKFZ* ; Schlemmer, H.-P.DKFZ* ; Paech, D.DKFZ* ; Ladd, M.DKFZ* ; Bachert, P. (Last author)DKFZ*

2019
Wiley-Liss New York, NY [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1002/mrm.27751

Abstract: Relaxation-compensated CEST-MRI (i.e., the inverse metrics magnetization transfer ratio and apparent exchange-dependent relaxation) has already been shown to provide valuable information for brain tumor diagnosis at ultrahigh magnetic field strengths. This study aims at translating the established acquisition protocol at 7 T to a clinically relevant magnetic field strength of 3 T.Protein model solutions were analyzed at multiple magnetic field strengths to assess the spectral widths of the amide proton transfer and relayed nuclear Overhauser effect (rNOE) signals at 3 T. This prior knowledge of the spectral range of CEST signals enabled a reliable and stable Lorentzian-fitting also at 3 T where distinct peaks are no longer resolved in the Z-spectrum. In comparison to the established acquisition protocol at 7 T, also the image readout was extended to three dimensions.The observed spectral range of CEST signals at 3 T was approximately ±15 ppm. Final relaxation-compensated amide proton transfer and relayed nuclear Overhauser effect contrasts were in line with previous results at 7 T. Examination of a patient with glioblastoma demonstrated the applicability of this acquisition protocol in a clinical setting.The presented acquisition protocol allows relaxation-compensated CEST-MRI at 3 T with a 3D coverage of the human brain. Translation to a clinically relevant magnetic field strength of 3 T opens the door to trials with a large number of participants, thus enabling a comprehensive assessment of the clinical relevance of relaxation compensation in CEST-MRI.

---

Contributing Institute(s):

1. Medizinische Physik in der Radiologie (E020)
2. Radiologie (E010)
3. Arbeitsgruppe Wirkstoffforschung (A390)

Research Program(s):

1. 315 - Imaging and radiooncology (POF3-315) (POF3-315)

Appears in the scientific report 2019

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; IF < 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---